A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes

Citation record

Study start

2026-11

NCT number

NCT07881458

Phase

Phase3

Overall status

Not Yet Recruiting

Study type

Interventional

Lead sponsor

Eli Lilly and Company

Enrollment

1,000 participants

Conditions

Obesity · Overweight · Diabetes Mellitus, Type 2

Interventions

eloralintide and tirzepatide (Drug) · Tirzepatide (Drug)

Last updated at source

19 Oct 2026

Original source

https://clinicaltrials.gov/study/NCT07881458

This page reproduces citation metadata only. Inclusion in the Avion Science research library does not imply endorsement and does not establish the safety, efficacy or intended use of any Avion Science compound. Refer to the original record for complete study information.